Product Description
TBA-7371 is an antimicrobial compound developed by TB Alliance inÊcollaboration with AstraZeneca. It is in a novel class of drugs known as DprE1 inhibitors, of which there are two other compounds in early development. With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.Ê (Sourced from: https://www.tballiance.org/news/tb-alliance-moves-two-novel-tuberculosis-drugs-human-trials)
Mechanisms of Action: DprE1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gates Medical Research Institute
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Tuberculosis, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| TBA-7371-CL001 | P1 |
Completed |
Tuberculosis, Pulmonary |
2018-07-08 |
2019-03-21 |
Treatments |
|
| Gates MRI-TBD03-201 | P2 |
Completed |
Tuberculosis, Pulmonary |
2022-10-05 |
2025-08-27 |